Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly
Por:
Oliver-Vila, I, Coca, MI, Grau-Vorster, M, Pujals-Fonts, N, Caminal, M, Casamayor-Genesca, A, Ortega, I, Reales, L, Pla, A, Blanco, M, Garcia, J, Vives, J
Publicada:
1 ene 2016
Resumen:
Background aims. Umbilical cord (UC) has been proposed as a source of mesenchymal stromal cells (MSCs) for use in experimental cell-based therapies provided that its collection does not raise any risk to the donor, and, similar to bone marrow and lipoaspirates, UC-MSCs are multipotent cells with immuno-modulative properties. However, some of the challenges that make a broader use of UC-MSCs difficult include the limited availability of fresh starting tissue, time-consuming processing for successful derivation of cell lines, and the lack of information on identity, potency and genetic stability in extensively expanded UC-MSCs, which are necessary for banking relevant cell numbers for preclinical and clinical studies. Methods. Factors affecting the success of the derivation process (namely, time elapsed from birth to processing and weight of fragments), and methods for establishing a two-tiered system of Master Cell Bank and Working Cell Bank of UC-MSCs were analyzed. Results. Efficient derivation of UC-MSCs was achieved by using UC fragments larger than 7 g that were processed within 80 h from birth. Cells maintained their immunophenotype (being highly positive for CD 105, CD90 and CD73 markers), multi-potentiality and immuno-modulative properties beyond 40 cumulative population doublings. No genetic abnormalities were found, as determined by G-banding karyotype, human telomerase reverse transcriptase activity was undetectable and no toxicity was observed in vivo after intravenous administration of UC-MSCs in athymic rats. Discussion. This works demonstrates the feasibility of the derivation and large-scale expansion of UC-MSCs from small and relatively old fragments of UC typically discarded from public cord blood banking programs.
Filiaciones:
Oliver-Vila, I:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Coca, MI:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Grau-Vorster, M:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Pujals-Fonts, N:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Caminal, M:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Casamayor-Genesca, A:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Ortega, I:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Reales, L:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Pla, A:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Blanco, M:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Garcia, J:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
Vives, J:
XCELLA, Div Terapies Avancades, Banc Sang & Teixits, Edifici Dr Frederic Duran i Jorda,Passeig Taulat, Barcelona 08005, Spain
|